Compare

Amneal Pharmaceuticals/$AMRX

1D1W1M3M6MYTD1Y5YMAX

About Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Ticker
$AMRX
Sector
Health
Primary listing
NASDAQ
Employees
8,700

AMRX Metrics

BasicAdvanced
$7.4B
52.92
$0.40
1.21
-

What the Analysts think about AMRX

Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.
Analyst projections of the future price of Amneal Pharmaceuticals stock.

Bulls say / Bears say

Third-quarter revenue rose 10% year on year and adjusted EBITDA grew 30%, prompting Amneal to raise its 2026 revenue, EBITDA and adjusted EPS guidance. That points to strong current trading across its portfolio. (Amneal Pharmaceuticals)
Amneal launched its FDA-approved lanreotide injection in September, adding a complex injectable to its growth portfolio. The reference product had nearly $1 billion in US sales over the year to July 2026, offering a sizeable market to pursue. (Amneal Pharmaceuticals)
Specialty revenue grew 20% in the third quarter, led by CREXONT, BREKIYA and UNITHROID. Continued uptake of these branded treatments could give Amneal a growth engine beyond generics. (Amneal Pharmaceuticals)
Operating cash flow was only $50 million in the first nine months of 2026, down from $210 million a year earlier. Amneal also cut its full-year cash-flow outlook, citing inventory build-up and delayed collections. (SEC, Amneal Pharmaceuticals)
The Kashiv deal has increased balance-sheet risk: net debt reached about $3.1 billion and net leverage rose to 3.9 times, from 3.5 times at the end of 2025. High leverage could limit flexibility if integration or growth falls short. (SEC)
Genentech and Novartis sued Amneal and Kashiv over nine patents tied to their proposed Xolair biosimilar. The dispute adds legal and launch-timing uncertainty to a product positioned as a future growth driver. (Bloomberg Law)
Data summarised monthly by Lightyear AI. Last updated on 14 Nov 2026.

AMRX Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

AMRX Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.